Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Gross Profit: 2010-2025

Historic Gross Profit for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to $26.3 million.

  • Heron Therapeutics' Gross Profit rose 12.62% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.6 million, marking a year-over-year increase of 15.30%. This contributed to the annual value of $105.6 million for FY2024, which is 70.55% up from last year.
  • As of Q3 2025, Heron Therapeutics' Gross Profit stood at $26.3 million, which was down 3.82% from $27.3 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Gross Profit high stood at $30.6 million for Q4 2024, and its period low was -$3.8 million during Q4 2021.
  • In the last 3 years, Heron Therapeutics' Gross Profit had a median value of $25.5 million in 2024 and averaged $22.9 million.
  • In the last 5 years, Heron Therapeutics' Gross Profit slumped by 134.17% in 2021 and then surged by 36,360.00% in 2023.
  • Over the past 5 years, Heron Therapeutics' Gross Profit (Quarterly) stood at -$3.8 million in 2021, then skyrocketed by 554.10% to $17.4 million in 2022, then skyrocketed by 39.92% to $24.3 million in 2023, then increased by 25.48% to $30.6 million in 2024, then increased by 12.62% to $26.3 million in 2025.
  • Its Gross Profit was $26.3 million in Q3 2025, compared to $27.3 million in Q2 2025 and $30.4 million in Q1 2025.